English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Concentration‐ QT cF data obtained from two phase I studies in healthy volunteers treated with a novel phosphodiesterase‐4 inhibitor currently under development for the treatment of chronic obstructive pulmonary disease were analyzed by means of mixed‐effects modeling. A simple linear mixed‐effects model and a more complex model that included oscillatory functions were employed and compared. The slope of the concentration‐ QT cF relationship was not significantly greater than 0 in both approaches, and the simulations showed that the upper limit of the 90%  confidence interval  around the mean ΔΔ QT cF is not expected to exceed 10 ms within the range of clinically relevant concentrations. An additional simulation study confirmed the robustness of the simple  linear mixed‐effects  model for the analysis of concentration‐ QT  data and supported the modeling of data obtained from studies with different designs (parallel and crossover).

cpt: pharmacometrics and systems pharmacology

Concentration–QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase‐4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation